Table 1.

Examples of Antibody-Like Proteins (ALPs) that may overcome competition effects from endogenous IgG^†.

Format	Name	Target	Disease	Development stage	Citation
Antibody fragments and single domain antibodies	huCD64 × MHC II	FcγRI and MHC II	B-cell lymphoma	Preclinical	[20]
	AFM13	FcγRIIIA and CD30 (BiTe)	Hodgkin’s lymphoma	Phase 2 (NCT04101331)	[21]
	GTB-3550	FcγRIIIA, IL-15 and CD33 (TriKE)	Haematological malignancies	Phase 2 (NCT03214666)	[22]
Glyco-optimised mAbs	Mogamulizumab	CCR4	T cell lymphomas	Approved	[23]
	Obinutuzumab	CD20	Chronic lymphocytic leukemia and follicular lymphoma	Approved	[24]
	TrasGEX	HER2	Solid tumours	Phase 1 (NCT01409343)	[25,26]
Fc-optimised mAbs	Margetuximab	HER2	Breast cancer	Approved	[27,28]
	T3-Ab	CD20	Non-hodgkin lymphoma	Preclinical	[29,30]
Fc multimers	KP3- IgG-3Fc	MrkA KP3	Klebsiella pneumoniae	Preclinical	[31]
	Stradobody™	EGFR	Colon cancer	Preclinical	[32]

^†C-C Motif Chemokine Receptor 4 (CCR4), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), bispecific T Cell Engager (BiTe), trispecific killer cell engager (TriKE).